Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.55 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839 | 1.00 | RPS6KA3 (1.00) | RPS6KA3ALDH1A1MAPTGSK3BPOLB | |
| SCHEMBL905690 | 1.00 | RPS6KA3 (1.00) | RPS6KA3ALDH1A1MAPTGSK3BPOLB | |
| SCHEMBL31434409 | 0.85 | RPS6KA3 (0.74) | RPS6KA3ALDH1A1MAPTPOLBHTT | |
| SCHEMBL1305323 | 0.82 | POLB (0.80) | RPS6KA3ALDH1A1GSK3BPOLBDYRK1A | |
| SCHEMBL1305325 | 0.82 | POLB (0.80) | RPS6KA3ALDH1A1GSK3BPOLBDYRK1A | |
| SCHEMBL5728158 | 0.81 | RPS6KA3 (0.68) | RPS6KA3ALDH1A1MAPTGSK3BPOLB | |
| SCHEMBL18499299 | 0.81 | RPS6KA3 (1.00) | RPS6KA3ALDH1A1MAPTGSK3BTDP1 | |
| SCHEMBL6849771 | 0.81 | RPS6KA3 (1.00) | RPS6KA3ALDH1A1MAPTGSK3BMEN1 | |
| SCHEMBL14660146 | 0.81 | RPS6KA3 (0.81) | RPS6KA3ALDH1A1MAPTGSK3BPOLB | |
| SCHEMBL29638294 | 0.81 | RPS6KA3 (0.72) | RPS6KA3ALDH1A1MAPTGSK3BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017176792-A1 | METHODS OF PREVENTING OR REDUCING A FIBROTIC RESPONSE USING CSF 1R INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2012025726-A1 | Novel Hybrid Compounds | UNIVERSITY OF GREENWICH (GB) | 2012-03-01 | — | — | WO | disclosed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2130829-A1 | NOVEL HYDROXYINDOLE DERIVATIVE | Theravalues Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | CSF1R, CSF3R, CD209 | RPS6KA3 2786/4885ALDH1A1 1112/4885MAPT 3341/4885 |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | RPS6KA3 1532/4885ALDH1A1 2136/4885MAPT 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.